Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study
Concomitant use of PPIs with ribociclib or palbociclib did not affect the efficacy of either CDK4/6 inhibitor. PPIs can be administered alongside these medications when clinically indicated.
Authors
- Oğur Karhan (ORCID: https://orcid.org/0000-0002-7140-8957)
- Yasin Sezgin (ORCID: https://orcid.org/0000-0003-4122-8389)
- Berrak Mermit Ercek
- Sezai Tunç (ORCID: https://orcid.org/0000-0002-4972-9367)
- Zuhat Urakçı (ORCID: https://orcid.org/0000-0003-3878-988X)
- Serdar İleri (ORCID: https://orcid.org/0000-0002-3739-3528)
- Hayati Arvas (ORCID: https://orcid.org/0000-0003-2215-5567)
- Diclehan Kılıç (ORCID: https://orcid.org/0000-0002-6568-0866)
Institutions
- Van Yüzüncü Yıl Üniversitesi (TR)
- Dicle University (TR)
- Şanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesi (TR)
- Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi (TR)
- Harran University (TR)
Publication Details
- Journal
- Oncology
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1159/000542693
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.42